Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action

Experimental and Molecular Pathology
Meena SharmaMahesh C Sharma

Abstract

Angiostatin, the N-terminal four kringles (K1-4) of parent molecule plasminogen, is reported to block Lewis Lung Carcinoma (LLC) tumor growth and metastasis. However, angiostatin's mechanism of action is unclear. We earlier reported that angiostatin binds to cell surface annexin II through the lysine-binding domain (kringles 1-4) [Tuszynski, G.P., Sharma, M., Rothman, V.L., Sharma, M.C., 2002. Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells. Microvasc. Res. 64:448-462.]). We now show that annexin II on the cell surface of LLC cells regulates conversion of plasminogen to plasmin. Activation of plasminogen to plasmin is time-dependent, with the linear activation lasting up to 120 min. Monoclonal antibodies to annexin II reduced plasminogen activation by 92.6%, suggesting a specific role of annexin II in plasmin generation. Angiostatin also reduced plasmin generation by 81.6%, suggesting that angiostatin may be competing with plasminogen through lysine-binding domain. epsilon-Aminocaproic acid, a lysine analogue, effectively blocked plasminogen activation indicating that, indeed, the lysine-binding site of the kringles domain is required for activation. These data su...Continue Reading

References

Feb 1, 1992·Scientific American·L A Liotta
Dec 2, 1990·Cell Differentiation and Development : the Official Journal of the International Society of Developmental Biologists·M S Pepper, R Montesano
Nov 3, 1995·International Journal of Cancer. Journal International Du Cancer·H KobayashiT Terao
Feb 1, 1993·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·F Blasi
Jan 1, 1993·Physiological Reviews·P Mignatti, D B Rifkin
Jun 1, 1996·Nature Medicine·M S O'ReillyJ Folkman
Jul 3, 1997·International Journal of Cancer. Journal International Du Cancer·P A AndreasenM J Duffy
Jul 30, 1997·Biochemical and Biophysical Research Communications·Z WuY Shing
May 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·F GriscelliH Lu
Mar 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·T L MoserS V Pizzo
May 26, 1999·Journal of the National Cancer Institute·R W StephensN Brünner
Aug 16, 2001·Proceedings of the National Academy of Sciences of the United States of America·F M BrichoryS M Hanash
Aug 22, 2001·The Journal of Biological Chemistry·T TaruiY Takada
Jun 28, 2002·The Journal of Biological Chemistry·Takehiko TaruiYoshikazu Takada
Sep 5, 2003·The Journal of Biological Chemistry·Olivier PeyruchaudPhilippe Clezardin
Sep 10, 2003·The Journal of Experimental Medicine·Bradley K McCollMarc G Achen
Jan 1, 2004·The Journal of Clinical Investigation·Qi LingKatherine A Hajjar
Apr 20, 2004·Journal of Cellular Biochemistry·Jing ZhouGeorge P Tuszynski
Sep 1, 2004·Virchows Archiv : an International Journal of Pathology·U ZimmermannJ Giebel

❮ Previous
Next ❯

Citations

Dec 4, 2013·Cell and Tissue Research·Gurpreet K AulakhBaljit Singh
Mar 5, 2014·Disease Markers·Chi-Yun Wang, Chiou-Feng Lin
Sep 13, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Noor A LokmanCarmela Ricciardelli
Jun 1, 2013·American Journal of Respiratory Cell and Molecular Biology·Michael SchuligaAlastair G Stewart
Mar 28, 2012·International Journal of Colorectal Disease·Volker SchmitzEsther Raskopf
Jul 9, 2008·Cancer Investigation·Yingchun HouNannan Zhang
Jun 30, 2015·American Journal of Respiratory Cell and Molecular Biology·Michael SchuligaAlastair G Stewart
Aug 24, 2012·Kidney International·Giovana Seno Di MarcoMarcus Brand
Apr 19, 2013·Experimental Hematology & Oncology·Patrizia CerutiFrancesco Novelli
Apr 17, 2015·Mediators of Inflammation·Michael Schuliga
Jan 28, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Suebwong ChuthapisithOleg Eremin
Jan 29, 2017·CNS Neuroscience & Therapeutics·Wei FangWan-Qing Liao
Mar 23, 2013·International Journal of Molecular Sciences·Alamelu BharadwajDavid Waisman
Jan 18, 2007·Journal of Cellular Biochemistry·Xuan ShangRongjia Zhou
Dec 7, 2007·Biological & Pharmaceutical Bulletin·Yasufumi KatanasakaNaoto Oku
Aug 14, 2008·The Journal of Pathology·S Mussunoor, G I Murray
Aug 21, 2018·International Journal of Cancer. Journal International Du Cancer·Mahesh C Sharma
Aug 21, 2015·Nature Communications·Kevin MoreauDavid C Rubinsztein
Nov 12, 2013·American Journal of Physiology. Lung Cellular and Molecular Physiology·Gurpreet K AulakhBaljit Singh
Jul 8, 2010·Journal of Cellular Physiology·Raquel Lima e SilvaPeter A Campochiaro
Jan 3, 2020·Cellular and Molecular Life Sciences : CMLS·Jennifer Pérez-BozaIngrid Struman
May 26, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Lan LuQiang Cheng
Jan 19, 2010·Experimental and Molecular Pathology·Meena SharmaMahesh C Sharma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.